Holen Sie sich die Stockscreener-App
208.89
0.56%
1.0743
Schlusskurs vom Vortag:
$207.82
Offen:
$207.97
24-Stunden-Volumen:
76,432
Relative Volume:
0.09
Marktkapitalisierung:
$10.95B
Einnahmen:
$708.24M
Nettoeinkommen (Verlust:
$-188.30M
KGV:
-55.87
EPS:
-3.7392
Netto-Cashflow:
$-70.99M
1W Leistung:
-0.44%
1M Leistung:
-1.76%
6M Leistung:
+27.05%
1J Leistung:
+66.29%
1-Tages-Spanne:
$205.75
$211.17
1-Wochen-Bereich:
$202.00
$211.17
52-Wochen-Spanne:
$112.90
$260.19
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
209.07 | 10.89B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
522.83 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.20 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.32 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.18 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | Eingeleitet | B. Riley Securities | Buy |
| 2025-09-03 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-07 | Eingeleitet | Jefferies | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-31 | Bestätigt | Mizuho | Outperform |
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Hsbc Holdings PLC Sells 12,653 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Is Axsome Therapeutics (NASDAQ:AXSM) Entering A Turning Point? - Kalkine Media
33,554 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Readystate Asset Management LP - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Seven Fleet Capital Management LP Grows Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
12,293 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Public Employees Retirement System of Ohio - MarketBeat
Corient Private Wealth LP Makes New $1.26 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome therapeutics COO Mark Jacobson sells $2.08m of company stock - Investing.com Nigeria
Axsome Therapeutics, Inc. $AXSM Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Axsome Therapeutics (AXSM) Institutional Ownership 2026 - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) COO Sells $2,086,500.00 in Stock - MarketBeat
Axsome Therapeutics (AXSM) COO sells 10,000 shares in pre-set trading plan - Stock Titan
Planned $2.1M Axsome Therapeutics (AXSM) stock sale set under pre-arranged trading plan - Stock Titan
Wells Fargo Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $256 - moomoo.com
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), BioMarin Pharmaceutical (BMRN) and Envista Holdings (NVST) - The Globe and Mail
Axsome Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Legal & General Group Plc Makes New $8.10 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Van ECK Associates Corp Has $7.17 Million Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
20,091 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Alyeska Investment Group L.P. - MarketBeat
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation - Yahoo Finance
Axsome Therapeutics' Auvelity Could Drive Revenue Beats After Launch in Alzheimer's Agitation, RBC Says - marketscreener.com
Wellington Management Group LLP Has $160.06 Million Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Insider Ups Holding During Year - Moomoo
HC Wainwright Reaffirms "Buy" Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
Axsome doses first patient in phase 3 smoking cessation trial - Investing.com
Axsome Therapeutics Starts Phase 3 Trial of AXS-05 for Smoking Cessation - marketscreener.com
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation - Yahoo Finance
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: A Biotech Gem with 43% Upside Potential - DirectorsTalk Interviews
Jupiter Topco LLC Makes New Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Jefferies Financial Group Inc. Invests $6.27 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Bank of New York Mellon Corp Acquires Shares of 197,226 Axsome Therapeutics, Inc. $AXSM - MarketBeat
Hsbc Holdings PLC Invests $13.67 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
28,826 Shares in Axsome Therapeutics, Inc. $AXSM Purchased by Seven Fleet Capital Management LP - MarketBeat
Panoramic Capital LLC Purchases New Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Ieq Capital LLC Makes New $1.89 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Algert Global LLC Sells 40,125 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
OMERS ADMINISTRATION Corp Takes Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
B. Metzler seel. Sohn & Co. AG Invests $2.26 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Great Lakes Advisors LLC Invests $1.65 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Enterprise value to EBIT forward of Axsome Therapeutics, Inc. – MUN:19X - TradingView
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism? - Stocktwits
AXSM Stock In Spotlight Ahead Of Key FDA Verdict On Alzheimer’s Drug This Week - Stocktwits
Zacks Research Upgrades Axsome Therapeutics (NASDAQ:AXSM) to "Hold" - MarketBeat
Lisanti Capital Growth LLC Acquires Shares of 20,825 Axsome Therapeutics, Inc. $AXSM - MarketBeat
Eagle Health Investments LP Invests $15.92 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Enterprise value to EBITDA forward of Axsome Therapeutics, Inc. – SWB:19X - TradingView
Axsome Therapeutics Inc (AXSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years - Sahm
Pallas Capital Advisors LLC Acquires Shares of 40,511 Axsome Therapeutics, Inc. $AXSM - MarketBeat
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Axsome Therapeutics Inc-Aktie (AXSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer |
Sep 03 '26 |
Sale |
208.65 |
10,000 |
2,086,500 |
0 |
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):